EGFR and non-small cell lung carcinoma: In a clinical study (NCT01734915), researchers used a noninvasive CTC and ctDNA analysis to detect the EGFR T790M mutation in NSCLC patients and predict their response to T790M-targeted EGFR inhibitors (Sundaresan et al., 2016).